2CBCB-NBOMe

2CBCB-NBOMe
Systematic (IUPAC) name
N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine
Clinical data
Legal status
  • Uncontrolled
Identifiers
CAS Number 1354634-09-5 N
ChemSpider 26234935 YesY
Chemical data
Formula C19H22BrNO3
Molar mass 392.286 g/mol
 NYesY (what is this?)  (verify)

2CBCB-NBOMe (NBOMe-TCB-2) is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2007 at Purdue University as part of the ongoing research program of the team led by David Nichols focusing on the mapping of the specific amino acid residues responsible for ligand binding to the 5HT2A receptor. 2CBCB-NBOMe acts as a potent and selective agonist for the 5-HT2A and 5-HT2C receptors, with a Ki of 0.27nM at the human 5-HT2A receptor, a similar potency to other agonists such as TCB-2, NBOMe-2C-I and Bromo-DragonFLY.[1]

Legality

2CBCB-NBOMe is a controlled substance in Vermont as of January 2016.[2]

See also

References

  1. Braden, Michael Robert (2007). Towards a biophysical understanding of hallucinogen action (PhD.). Purdue University.
  2. "Regulated Drugs Rule" (PDF). Vermont Department of Health. Retrieved 14 October 2015.
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.